Trial: 201710193

AALL1621 – A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Phase

II

Principal Investigator

Hayashi, Robert

Disease Site

Lymphoid Leukemia; Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov